Natpara Logo
Natpara Logo

Understanding Hypoparathyroidism

Hypoparathyroidism interferes with calcium homeostasis2

Hypoparathyroidism is a complex endocrine disorder characterized by absent or inappropriately low levels of parathyroid hormone (PTH). Compromised endogenous PTH function can lead to hypocalcemia.2-4

Calcium levels can be maintained through interactions that involve endogenous PTH and the bones, kidneys, intestines, and the active form of vitamin D2

Insufficient endogenous PTH can interfere with certain processes of these organs which can lead to2,3:

  • Decreased intestinal calcium absorption due to a decrease in the conversion of vitamin D to its active form
  • Decreased renal reabsorption of calcium
  • Decreased bone turnover

References: 1. NATPARA [package insert]. Shire-NPS Pharmaceuticals, Inc. 2. Shoback D. Clinical Practice. Hypoparathyroidism. N Engl J Med. 2008;359(4):391-403. 3. Bilezikian JP, Khan A, Potts JT Jr, et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res. 2011;26(10):2317-2337. 4. Fong J, Khan A. Hypocalcemia: updates in diagnosis and management for primary care. Can Fam Physician. 2012;58(2):158-162.

NATPARA® is a registered trademark of Shire-NPS Pharmaceuticals, Inc.

OnePath® is a registered trademark of Shire or its affiliates.

Q-Cliq is a trademark of Shire-NPS Pharmaceuticals, Inc.